<DOC>
	<DOCNO>NCT00970385</DOCNO>
	<brief_summary>This multicenter randomize trial evaluate induction treatment VIP-reinforced-ABVD ( VIP-rABVD ) versus CHOP/21 patient newly diagnose peripheral T cell lymphoma .</brief_summary>
	<brief_title>Study About Treatment Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>Induction therapy : ARM 1 : 6 Chemotherapy course = 3 VIP alternate 3 ABVD ARM 2 : 8 Chemotherapy course = CHOP every 21 day Consolidation therapy : For patient CR = radiotherapy 40GY / 5X1,8 GY per week</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>newly diagnose untreated PTCL age 18 70 year performance status â‰¤ 2 Ann Arbor stage I IV normal cardiac ventricular ejection fraction 50 % normal hepatic function ( asat , ALAT , PAL &lt; 2.5 ULN ) cutaneous form PTCL previous treatment age &lt; 18 &gt; 70 performance status &gt; 2 abnormal cardiac hepatic function HIV , HCV HBV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>